These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 36993127)

  • 1. Adverse effects after first and second dose of covishield and covaxin: A longitudinal study.
    Mittal A; Jain B; Varshney AM; Garg G; Sachan D; Singh RB
    J Family Med Prim Care; 2022 Nov; 11(11):7339-7345. PubMed ID: 36993127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulated Reporting of Adverse Events Following Immunization with COVID-19 Vaccines.
    Jhaj R; Chaudhary D; Shukla AK; Yadav J
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Events Following COVID-19 Vaccination in Selected Apartments in Bangalore, India.
    Chakraborty A; Reval N; Kamath L
    Cureus; 2022 Feb; 14(2):e21809. PubMed ID: 35291520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse events following ChAdOx1 nCoV-19 Vaccine (COVISHIELD) amongst health care workers: A prospective observational study.
    Kamal D; Thakur V; Nath N; Malhotra T; Gupta A; Batlish R
    Med J Armed Forces India; 2021 Jul; 77(Suppl 2):S283-S288. PubMed ID: 34334895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and determinants of adverse events following ChAdOx1 nCoV-19 vaccination (COVISHIELD) - A retrospective cohort study among healthcare workers in central Karnataka, India.
    Davalagi SB; Nayak VP; Ghose A; Marakatti SS; Kasturi ES; Maganahalli AS
    J Family Med Prim Care; 2023 Nov; 12(11):2869-2874. PubMed ID: 38186765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of COVID-19 Vaccination on Menstrual Cycle Patterns of Reproductive-age Women: A Multi-centric Observational Study.
    Kumar N; Gangane N; Mohapatra I; Rukadikar C; Sharmila V; Pushpalatha K; Eerike M; Santhoshi G; Samantaray SR; Seth S; Trigunait P; Reddy NJ; Patel S; Rani S; Mishra R; Negi K
    Curr Drug Res Rev; 2024; 16(2):237-248. PubMed ID: 37291775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of Early Adverse Events Following Covishield (ChAdOx1 nCoV-19) Vaccination: A Prospective Study.
    Velhal GD; Kamath YV; Agrawal AS; Vora DS; Dwivedi VR
    Indian J Community Med; 2022; 47(4):613-617. PubMed ID: 36742958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adverse Events Following COVISHIELD and VERO CELL Vaccination Campaigns Against COVID-19.
    Adhikari S; Maharjan J; Bhattarai S; Kunwar K; Agrawal S; Dangal RK; Chapagain RH; Bista TB; Bhattarai S
    J Nepal Health Res Counc; 2024 Mar; 21(4):651-658. PubMed ID: 38616598
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covid-19 Vaccines Available in India.
    Mukim M; Sharma P; Patweker M; Patweker F; Kukkar R; Patel R
    Comb Chem High Throughput Screen; 2022; 25(14):2391-2397. PubMed ID: 35293291
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Longitudinal Follow-Up Study on the Side Effects of COVID-19 Vaccines: A Telephonic Questionnaire Approach.
    Priya Jakkula K; Kishore J; Maheswar Rao U
    Cureus; 2024 Jun; 16(6):e62917. PubMed ID: 39040783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimation of SARS-CoV-2 IgG Antibodies in Healthcare Worker-Administered Covishield and Covaxin Vaccines at a Tertiary Care Hospital in Jharkhand, India.
    Singh B; Seema K; Mahuli AV; Kumar A; Boipai M; Sharma AK; Kumar M; Kumar S; Chandra S; Shahi AK
    Cureus; 2023 Oct; 15(10):e47566. PubMed ID: 38021860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody response after first and second-dose of ChAdOx1-nCOV (Covishield
    Singh AK; Phatak SR; Singh R; Bhattacharjee K; Singh NK; Gupta A; Sharma A
    Vaccine; 2021 Oct; 39(44):6492-6509. PubMed ID: 34600747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of safety and adverse drug reactions of COVID vaccination in the South Indian population: An observational prospective cross-sectional study.
    Manda A; Koya P; Pallem R; Mohd D; Thatikonda K; Venkateshwarlu K
    Ann Med Surg (Lond); 2022 Dec; 84():104948. PubMed ID: 36536701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of BBV152/Covaxin and AZD1222/Covishield vaccines against severe COVID-19 and B.1.617.2/Delta variant in India, 2021: a multi-centric hospital-based case-control study.
    Bhatnagar T; Chaudhuri S; Ponnaiah M; Yadav PD; Sabarinathan R; Sahay RR; Ahmed F; Aswathy S; Bhardwaj P; Bilimale A; Kumar MS; Logaraj M; Narlawar U; Palanivel C; Patel P; Rai SK; Saxena V; Singh A; Thangaraj JW; Agarwal A; Alvi Y; Amoghashree ; Ashok P; Babu D; Bahurupi Y; Bhalavi S; Behera P; Biswas PP; Charan J; Chauhan NK; Chetak KB; Dar L; Das A; Deepashree R; Dhar M; Dhodapkar R; Dipu TS; Dudeja M; Dudhmal M; Gadepalli R; Garg MK; Gayathri AV; Goel AD; Gowdappa HB; Guleria R; Gupta MK; Islam F; Jain M; Jain V; Jawahar MLS; Joshi R; Kant S; Kar SS; Kalita D; Khapre M; Khichar S; Kombade SP; Kohli S; Kumar A; Kumar A; Kumar D; Kulirankal KG; Leela KV; Majumdar T; Mishra B; Misra P; Misra S; Mohapatra PR; Murthy MN; Nyayanit DA; Patel M; Pathania M; Patil S; Patro BK; Jalandra R; Rathod P; Shah N; Shete A; Shukla D; Shwethashree M; Sinha S; Sumana MN; Surana A; Trikha A; Tejashree A; Venkateshan M; Vijaykrishnan G; Wadhava S; Wig N; Gupta N; Abraham P; Murhekar MV
    Int J Infect Dis; 2022 Sep; 122():693-702. PubMed ID: 35843496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with development of adverse events after taking COVID-19 vaccine in a tribal state of India: Regression analysis.
    Kujur M; Kiran KA; Nag AR; Soren SK; Kujur A
    J Family Med Prim Care; 2022 Oct; 11(10):6260-6267. PubMed ID: 36618180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determinants of associated events following AZD1222 (Covishield) vaccination in a high-risk population in Nepal.
    Poudel KM; Shah N; Prakash M; Deo SK; Bhandari S; Poudel TR
    BMC Infect Dis; 2022 May; 22(1):422. PubMed ID: 35505278
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events following immunization of COVID-19 (Covaxin) vaccine at a tertiary care center of India.
    Parida SP; Sahu DP; Singh AK; Alekhya G; Subba SH; Mishra A; Padhy BM; Patro BK
    J Med Virol; 2022 Jun; 94(6):2453-2459. PubMed ID: 35149993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Study to Describe the Pattern of Cutaneous Adverse Effects of COVID-19 Vaccines (Covishield and Covaxin).
    Saraswat N; Tripathy DM; Murali M; Boruah J; Mitra D; Chopra H; Bhatnagar A
    Indian Dermatol Online J; 2023; 14(6):814-820. PubMed ID: 38099027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.